Effect of female coronavirus disease 2019 vaccination on assisted reproductive outcomes: a systematic review and meta-analysis

Huang, Jialyu; Zheng, Fang; Liu, Yiqi; Xing, Chutian; Huang, Lingling; Mao, Jiaqin; Chen, Houyang; Huang, Zhihui; Xia, Leizhen; Tang, Liang; Zhang, Zhiqin; Bing-qin, Liu; Hua, Huang; Tian, Lifeng; Ai, Xiaoyan; Wu, Qiongfang

doi:10.1016/j.fertnstert.2023.01.024

Cited by 8 publications

(7 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since these women are often confronted with higher levels of anxiety and depression, 46 our reassuring data may also help to reduce the psychiatric stress and further protect them from potential negative consequences 47–49 . Of note, this study did not preclude the importance of timely COVID‐19 vaccination, which has shown its effectiveness in reducing morbidity and mortality as well as safety for assisted reproductive outcomes 50,51 …”

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

Impact of prior coronavirus disease 2019 infection in females on assisted reproductive outcomes: A systematic review with meta‐analysis

Liu,

Chen,

Chen

et al. 2023

Clinical and Translational Dis

Self Cite

View full text Add to dashboard Cite

ObjectivesTo investigate the relationship between prior coronavirus disease 2019 (COVID‐19) infection in females and subsequent treatment outcomes of assisted reproductive technology (ART).MethodsA systematic literature review was carried out up to 16 December 2022, in PubMed, Web of Science, EMBASE, and Cochrane Library. Random‐effect models were adopted to estimate the pooled effects as mean differences (MDs) or odds ratios (ORs). I2 statistic and Egger's test were applied to assess heterogeneity and publication bias, respectively.ResultsAfter screening 1480 records, 15 cohort studies totalling 1905 cycles were included in this meta‐analysis. In a comparison of previously COVID‐19‐infected versus uninfected women, no significant differences were observed in the primary outcomes of the retrieved oocytes number (MD = 0.06; 95% confidence interval [CI]: ‐0.75–0.88; I2 = 0) and clinical pregnancy rate (OR = 0.96; 95% CI: 0.74–1.24; I2 = 0). Pooled analyses of other predefined outcomes, which encompassed four cycle characteristics, six laboratory indicators and four pregnancy results, also showed no adverse effects of prior COVID‐19 infection. Most outcomes remained consistent after further sensitivity and subgroup analyses, and no significant publication bias was observed.ConclusionsOur work provides the first systematic evidence that COVID‐19 infection history in females may have no measurable detrimental impact on the subsequent ART cycle. More data are needed to assess the live birth outcome and the optimal time interval from infection to assisted reproduction.

show abstract

Section: Discussionmentioning

confidence: 91%

“…[47][48][49] Of note, this study did not preclude the importance of timely COVID-19 vaccination, which has shown its effectiveness in reducing morbidity and mortality as well as safety for assisted reproductive outcomes. 50,51…”

Section: Discussionmentioning

confidence: 99%

Impact of prior coronavirus disease 2019 infection in females on assisted reproductive outcomes: A systematic review with meta‐analysis

Liu,

Chen,

Chen

et al. 2023

Clinical and Translational Dis

Self Cite

View full text Add to dashboard Cite

show abstract

“…Direct or indirect harmful effects on fertility, embryo/fetal development, pregnancy outcome, parturition, or short-term postnatal development of offspring were not detected [ 75 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 ]. A recent metaanalysis did not find significant differences in assisted reproductive outcomes between vaccinated and unvaccinated women [ 98 ]. The minimal amount of vaccine that is detected in breast milk and ingested by the infant is likely to be inactivated by the infant’s digestive system, and hence unlikely to pose risks to the infant’s health [ 99 , 100 ].…”

Section: Discussionmentioning

confidence: 99%

COVID-19 Pharmacotherapy in Pregnancy: A Literature Review of Current Therapeutic Choices

Akinosoglou

Schinas

Rigopoulos

et al. 2023

Viruses

View full text Add to dashboard Cite

The clinical management of COVID-19 in pregnant women, who are considered a vulnerable population, remains uncertain even as the pandemic subsides. SARS-CoV-2 affects pregnant individuals in multiple ways and has been associated with severe maternal morbidity and mortality, as well as neonatal complications. The unique anatomy and physiology of gestation make managing COVID-19 in this population a complex and challenging task, emphasizing the importance of spreading knowledge and expertise in this area. Therapeutic interventions require distinct clinical consideration, taking into account differences in pharmacokinetics, vertical transmission, drug toxicities, and postnatal care. Currently, there is limited data on antiviral and immunomodulating COVID-19 pharmacotherapy in pregnancy. Some medication has been shown to be safe and well tolerated among pregnant women with COVID-19; however, the lack of randomized clinical trials and studies in this patient population is evident. Available vaccines are considered safe and effective, with no evidence of harm to the fetus, embryo development, or short-term postnatal development. Pregnant women should be counseled about the risks of SARS-CoV-2 infection and informed of available ways to protect themselves and their families. Effective treatments for COVID-19 should not be withheld from pregnant individuals, and more research is needed to ensure the best outcomes.

show abstract

“…Furthermore, although their analysis reports biochemical and clinical pregnancy outcomes, several other parameters are not addressed, such as oocyte yield, ongoing pregnancy, and live-birth rates. A more recent study by Huang et al, 46 however, did include a greater number of more recent studies. Their analysis included 21 studies and did find a statistically significant increase in mature oocytes but not in any other outcomes.…”

Section: Discussionmentioning

confidence: 99%

Coronavirus Disease 2019 (COVID-19) Vaccination and Assisted Reproduction Outcomes

Chamani

Taylor

Dadoun

et al. 2023

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

OBJECTIVE: To assess the association between coronavirus disease 2019 (COVID-19) vaccination and female assisted reproduction outcomes through a systematic review and meta-analysis. DATA SOURCES: We searched Medline (OVID), EMBASE, Web of Science, Cochrane Library, and ClinicalTrials.gov on January 11, 2023, for original articles on assisted reproduction outcomes after COVID-19 vaccination. The primary outcome was rates of clinical pregnancy; secondary outcomes included number of oocytes retrieved, number of mature oocytes retrieved, fertilization rate, implantation rate, ongoing pregnancy rate, and live-birth rate. METHODS OF STUDY SELECTION: Two reviewers independently screened citations for relevance, extracted pertinent data, and rated study quality. Only peer-reviewed published studies were included. TABULATION, INTEGRATION, AND RESULTS: Our query retrieved 216 citations, of which 25 were studies with original, relevant data. Nineteen studies reported embryo transfer outcomes, with a total of 4,899 vaccinated and 13,491 unvaccinated patients. Eighteen studies reported data on ovarian stimulation outcomes, with a total of 1,878 vaccinated and 3,174 unvaccinated patients. There were no statistically significant results among our pooled data for any of the primary or secondary outcomes: clinical pregnancy rate (odds ratio [OR] 0.94, 95% CI 0.88–1.01, P=.10), number of oocytes retrieved (mean difference −0.26, 95% CI −0.68 to 0.15, P=.21), number of mature oocytes retrieved (mean difference 0.31, 95% CI −0.14 to 0.75, P=.18), fertilization rate (OR 0.99, 95% CI 0.87–1.11, P=.83), implantation rate (OR 0.92, 95% CI 0.84–1.00, P=.06), ongoing pregnancy rate (OR 0.95, 95% CI 0.86–1.06, P=.40), or live-birth rate (OR 0.95, 95% CI 0.78–1.17, P=.63). A subanalysis based on country of origin and vaccine type was also performed for the primary and secondary outcomes and did not change the study results. CONCLUSION: Vaccination against COVID-19 is not associated with different fertility outcomes in patients undergoing assisted reproductive technologies. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42023400023.

show abstract

Effect of female coronavirus disease 2019 vaccination on assisted reproductive outcomes: a systematic review and meta-analysis

Cited by 8 publications

References 47 publications

Impact of prior coronavirus disease 2019 infection in females on assisted reproductive outcomes: A systematic review with meta‐analysis

Impact of prior coronavirus disease 2019 infection in females on assisted reproductive outcomes: A systematic review with meta‐analysis

COVID-19 Pharmacotherapy in Pregnancy: A Literature Review of Current Therapeutic Choices

Coronavirus Disease 2019 (COVID-19) Vaccination and Assisted Reproduction Outcomes

Contact Info

Product

Resources

About